| (Values in U.S. Thousands) | Dec, 2015 | Dec, 2014 | Dec, 2013 | Dec, 2012 | Dec, 2011 |
| Sales | 7,170 | 6,000 | 1,300 | 590 | 520 |
| Sales Growth | +19.50% | +361.54% | +120.34% | +13.46% | -76.04% |
| Net Income | -15,320 | -10,690 | -16,270 | -8,180 | -13,150 |
| Net Income Growth | -43.31% | +34.30% | -98.90% | +37.79% | -8.77% |
Wafergen Bio-Sys Cmn (WGBS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
WaferGen Biosystems, Inc., a development stage company, engages in the development, manufacture, and sale of systems for gene expression, genotyping, and stem cell research for the life sciences, pharmaceutical industries, biomarker discovery and diagnostic products industries. The company is actively developing its SmartChip(TM) product for the gene expression and genotyping markets. This innovative system, combined with next-generation chemistry and optimized assays being developed by WaferGen, promises to deliver significant speed and cost advantages to researchers in the gene expression and genotyping markets. It offers SmartSlide Micro-Incubation system that provides a controlled environment and physiological conditions for imaging studies, allowing researchers to characterize, differentiate, and proliferate various cells. WaferGen's revolutionary systems are the first of their kind, providing researchers with critical performance advantages that are not available with existing technologies.
Fiscal Year End Date: 12/31